HHS updates its national dementia plan, prioritizing risk reduction, early detection, biomarkers, and faster diagnostics and treatments through new FDA, CMS, and ARPA-H initiatives.
News|Articles|December 2, 2024
Presenting Our December Theme: Year in Review
Author(s)Leah Kuntz
Listen
0:00 / 0:00
Key Takeaways
- Psychiatric Times invites clinicians to reflect on their year's learnings and share insights with peers, focusing on psychiatric practice advancements.
- Contributions can include opinion pieces, case studies, or CME articles, promoting knowledge exchange among psychiatric professionals.
Do you want to be featured in our online series? Check out our December theme!
Advertisement
This year, Psychiatric Times is featuring monthly themes that speak to various aspects of psychiatry and issues relevant to psychiatric clinicians. Our December theme asks us to look back at this year with a clinical eye: What did you learn this year in your psychiatric practice? What do you want to share with your fellow clinicians? What populations are currently underserved and how can we help?
If you have something you want to share, whether that's an opinion piece, case study example, or CME article, let us know! Write to us now at
Advertisement
Related to this article
Neflamapimod misses its main DLB endpoint, but biomarker and subgroup signals suggest IL-1β pathway impact and may justify a phase 3 trial.
A systematic review and meta-analysis compares pharmacological agents with nonpharmacologic approaches to identify the most effective interventions for insomnia in peri- and postmenopausal women.
National survey shows most US adults don’t know AUD medications exist, and safety concerns plus racial disparities shape hesitation toward treatment.
GLP-1 drugs may quiet cravings by reshaping brain reward and satiety signals, reducing food-seeking drive and binge-like eating, while long-term effects remain unclear.
Breakthrough Alzheimer updates: UK adaptive platform trial tests repurposed drugs, new phase 2/3 therapies advance, and sleep disruption emerges as a treatable risk factor.
Behind the scenes at a psychiatry conference, Gus Alva, MD, DFAPA, and Erin Crown share practical insights on burnout, industry, and emerging treatments—turning continuing education into better patient outcomes.
Phase 2 trial shows daridorexant boosts pediatric insomnia sleep time up to 50 minutes, including ADHD/ASD patients, with strong safety and phase 3 plans.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Burnout, Gratitude, and the Value of Staying Current: On the Mind of Gus Alva, MD, DFAPA
2
Daridorexant, Orexin Receptor Agonist, Shows Positive Results in Pediatric Insomnia
3
Dementia Pipeline Update: Phase 2 and 3 Developments in Alzheimer Disease and Lewy Body Dementia
4
Food Noise and GLP-1 Drugs: What Research Reveals About Motivation and Appetitive Drive
5